Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
about
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breastPreviously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray dataThe potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivoApplication of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinomaInferring tumour purity and stromal and immune cell admixture from expression dataExpression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development.Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions.Emerging drugs for renal cell carcinoma.Management of locally advanced renal cell carcinoma.CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer.Active and passive immunotherapy: vaccines and antibodies.Antibody therapy in renal cell carcinoma.Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma.Carbonic anhydrase IX: historical and future perspectives.Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia.Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.Antibody-specific detection of CAIX in breast and prostate cancers.Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinomaCarbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.Immunological therapy in urological malignancy: novel combination strategies.Ultrasound-based combination therapy: potential in urologic cancer.Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases.Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.Immunostimulatory activity of dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A for renal cell carcinoma.Next revolution in molecular theranostics: personalized medicine for urologic cancers.ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors.Targeting ion transport in cancerRNA sequencing reveals upregulation of RUNX1-RUNX1T1 gene signatures in clear cell renal cell carcinomaDepletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.
P2860
Q24685857-2C19C7A6-420A-41BC-AE98-0C9F969CCBDAQ24805313-A7954354-E219-4999-88F0-4A616750913CQ26827175-B12E3956-1D70-49BC-812F-06A6D504C81EQ27026961-F1239AF1-AFD5-47B2-9B80-F374DC7F4575Q30674996-28F4BBD4-9E78-42CA-8A9D-9752D615060FQ33418774-017C4DD8-62D3-4351-91F7-656D87AB110AQ33540178-AEB1BDBB-2FDF-41D0-BF32-9B56A47E0EBEQ33860879-0528A017-A42A-4F25-B932-42E25D291B34Q34592273-D5901483-7BF1-459F-B50A-572591653AE1Q35015917-1D993259-457F-4370-9418-5318AC8CD668Q36302842-136ED7DA-D4F2-41F1-9168-ABA10F930CC0Q36555667-2278152F-2E17-4DEA-B036-1751E90673F3Q36612144-0473508A-5D53-4CFA-93CC-FF6CB806CE3AQ36696911-8D870B78-3CC1-403F-A20D-3354EFF24B92Q36736462-8622E2EB-9D48-415D-B5E4-E8384D69E0F0Q36794818-485DB141-BF4F-4039-9E9E-E435BD84AB07Q37073600-ABEE0DB7-3097-4BFE-89AB-49BC83442987Q37134628-437ADA7F-228F-48D7-BFA8-31A5E8505990Q37145154-BF7303E3-9D42-4E9D-998A-8F7DFC08091AQ37145159-689EB00A-696E-45E6-8268-C3870E42442FQ37145167-F371D804-4592-4314-ACB0-CCFD0435F5EDQ37330712-3D12B679-DECB-466E-B82C-6DA9E23A332FQ37383084-C38AE550-8805-48F4-8099-1162E03FEEF3Q37575248-5322A00C-37AE-4461-B5D1-33218BF0C152Q37754473-49443F0B-E02B-4094-974A-E5251E2380D4Q37809109-584C1212-4CC8-4C19-AB23-398331B3C289Q37821902-FC7AB060-8170-46EE-B723-BB57773FAFE4Q38154554-750FB1B2-0B7F-4984-8B3C-042A81833678Q38467824-B47B116B-A656-459D-8488-3284E663A515Q38476561-5CF8DF9D-05C1-4501-8509-74A550C8F9EBQ38559336-33F71D8D-12EB-4D47-A5BA-5C51CA852490Q39148640-F490FB91-524F-41BA-89CE-DDBD0EC7B504Q41666673-4F9F4400-78CB-44DE-9524-A5EB0107A748Q41930187-058ACD57-1465-4B5E-B56E-FDF7AE483F45Q42361297-BD5AC59D-ABAC-47DD-9FEF-24FB88C81DCCQ42511795-097D0868-E024-4011-BE60-A889B4679D91
P2860
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@ast
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@en
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@nl
type
label
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@ast
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@en
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@nl
prefLabel
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@ast
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@en
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@nl
P2093
P2860
P1476
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
@en
P2093
A Van Bokhoven
E Noessner
E Oosterwijk
J C Oosterwijk-Wakka
J L Vissers
K Grabmaier
M C De Weijert
P A Mulders
P2860
P304
P356
10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q
P407
P50
P577
2000-03-01T00:00:00Z